LONDON, UK, 16 November 2026 – Concr, the techbio company whose FarrSight® platform models and predicts how cancer therapies will perform, today announced a collaboration with Frontivia Global, the newly launched commercial arm of the not-for-profit clinical research organisation Frontier Science (Scotland) Ltd. The partnership aims to help sponsors design better, more reliable trials and accelerate the development of their oncology assets, including in rare cancers, by modelling therapeutic efficacy across candidate trial designs before and throughout clinical development.
Cancer drug development has one of the lowest success rates of any major disease area. Only about 5% of oncology programmes entering Phase I reach approval, against roughly 8% across all disease areas. Many of the choices that set those odds are fixed at the protocol stage: which patients to enrol, how many, on which endpoints and against which comparator.
The joint service is designed to inform those choices. Sponsors bring the data they already hold, from pre-clinical results to any early clinical readouts, and FarrSight® simulates the design options under consideration and explores new ones. Concr reports the predicted efficacy outcomes and trade-offs of each option, and the sponsor decides which to take forward. Frontivia Global’s statisticians and trial team then carry that design into the protocol and through data management, biostatistics and statistical programming, and study delivery. As trial data accrue, the model can be updated to inform the next decision. Modelling and delivery are planned together from the start.
Regulators are moving the same way. ICH M15, the first ICH guideline dedicated to model-informed drug development (MIDD), was finalised this year and encourages sponsors to plan modelling early, including for trial design. The US FDA’s draft guidance on Bayesian methods, issued in January, sets out how prior information can be combined with trial data. The MHRA 2030 Strategy, published on 14 October, commits the agency to building its capability to assess in silico evidence, including new guidance on digital twins and support for hybrid trials that use them. For sponsors, this means planning modelling alongside the trial rather than commissioning it after protocol lock.
Dr Irina Babina, Chief Executive Officer of Concr, commented: “Most sponsors hold more evidence than they can use. FarrSight® makes the data they already have work harder, simulating how a programme could play out before more patients and capital are committed. That gives sponsors a sharper evidence case for their asset, and it is the same case partners, investors, HTA bodies and regulators want to see: where the probability of success is highest, what the next study should cost, and how quickly they can get there. Decisions stay with the sponsor and their trial team; our job is to reduce the uncertainty around them.”
Dr Darren Gibson, Chief Executive Officer of Frontivia Global and Executive Director of Frontier Science (Scotland), added: “The launch of our independent subsidiary, Frontivia Global, our CRO, combines our 25+ years of experience and worldwide academic research with the same rigour, pace and accountability of commercial delivery. We understand timelines, investor pressures and regulatory scrutiny, and we deliver with precision and passion with a commercial focus, scientific excellence, patient focus and academic depth. Providing FarrSight®’s MIDD predictive intelligence will be used to inform the established methods our team uses to design and analyse each study.”
The collaboration is aimed at sponsors who need to reduce uncertainty in an asset’s development plan while clinical data are still limited. That includes biotechs taking an oncology asset into first-in-human and Phase II trials, where the design must stand up to scrutiny from investors and partners; pharma and biotech teams de-risking early-phase programmes; and academic and institutional groups planning investigator-led trials. The service is intended to cover small molecules, antibody-drug conjugates (ADCs), and cell and gene therapies.
Sponsors planning oncology trials can meet both teams at Frontivia Global’s launch in Scotland House, London, today, or during London Life Sciences Week. To arrange a meeting, get in touch or email bd@concr.co or enquiries@frontiviaglobal.com.
- ENDS -
About Concr Ltd
Concr is a global, UK-headquartered techbio company applying astrophysics-derived Bayesian AI to simulate human cancer biology and drive Model-Informed Drug Development (MIDD). Uniquely engineered to overcome the limitations of traditional “big data” AI by generating predictive patient-level digital twins from sparse and fragmented multi-modal data, Concr delivers precision from early biomarker discovery through to simulated clinical trials and synthetic control arms. Validated in partnership with industry leaders like Roche and Debiopharm and premier clinical centres including The Royal Marsden and NHS Christie, Concr provides drug developers with the biological fidelity needed to de-risk R&D and accelerate effective cancer therapies to market.
About Frontivia Global Ltd
Frontivia Global is an independent subsidiary of Frontier Science Scotland. Frontivia Global combines 25+ years of clinical trial development with the scientific depth of an internationally respected clinical research organisation and the agile, accountable, and responsive approach required by pharma, biotech, diagnostic and academic sponsors. Small enough to care. Big enough to deliver. Our multidisciplinary teams bring expertise across site start-up, project management and clinical delivery, biometrics, quality assurance and regulatory strategy, helping sponsors generate robust evidence, meet regulatory requirements and progress clinical development. For more information: Frontivia Global | Excellence in Clinical Trials
About Frontier Science (Scotland) Ltd
Frontier Science (Scotland) is a not-for-profit Scottish charity [SC033112], based in Scotland, with around 25+ years of experience in trial data management, biostatistics and study operations. Frontier Science (Scotland) aims to advance the education of the public in the field of clinical trials and statistical methodologies, for the benefit of the public.
Disclosures
Concr products and services are for research use only. They are intended to support research and strategic decision-making in therapeutic and diagnostic development. They are not a medical device and are not intended to diagnose, treat, cure, or prevent any disease.
Media contacts
Emre Misirlioglu | Concr | emre@concr.co
Michael Gilkes | Frontivia Global | Michael.gilkes@frontiviaglobal.com
Back